Form 4: Benitec Biopharma Director Receives Stock Options

Benitec Biopharma Inc. Director Sharon Mates was granted 31,500 stock options with an exercise price of $12.83, set to vest by December 1, 2026.

Summary

• Sharon Mates, a Director of Benitec Biopharma Inc. (BNTC), was granted 31,500 stock options.
• The options have an exercise price of $12.83 per share.
• The transaction date for the grant was January 22, 2026.
• These options expire on January 22, 2036.
• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.
• Following this transaction, Sharon Mates beneficially owns 31,500 derivative securities (options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as neutral to slightly positive as it aligns management incentives with shareholder interests, but it does not provide new operational or financial performance data.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options were granted at a price of $0, indicating they are part of a compensation package rather than a purchase.

Negatives

• Potential for future dilution if the options are exercised, increasing the number of outstanding shares.

Risks

• Future dilution of existing shareholders if the 31,500 options are exercised.
• The value of the options is dependent on the future stock price exceeding the exercise price of $12.83.

Future Outlook

The stock options are set to vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026, indicating a future milestone for the director's compensation.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent and align their interests with long-term shareholder value creation.

Related Party Transactions

• Grant of 31,500 stock options to Sharon Mates, a Director of Benitec Biopharma Inc., with an exercise price of $12.83 and an expiration date of January 22, 2036.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options; improved alignment of director's interests with long-term shareholder value.
• Management/Directors: Sharon Mates receives a significant equity incentive, linking her compensation to the company's stock performance.

Next Steps

• Vesting of the 31,500 stock options on the earlier of the next annual stockholders' meeting or December 1, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, stock options, director compensation, insider transaction, Form 4, equity grant, corporate governance